Intrapulmonary Drug Delivery of Salmon Calcitonin |
| |
Authors: | L J Deftos J J Nolan B L Seely P L Clopton G J Cote C L Whitham L J Florek T A Christensen M R Hill |
| |
Institution: | (1) Department of Medicine, University of California, San Diego, CA, USA, US;(2) The San Diego VA Medical Center, La Jolla, CA, USA, US;(3) Dura Pharmaceuticals, San Diego, CA, USA, US |
| |
Abstract: | SUMMARY
Calcitonin (CT) and other bone-active peptides have been restrained in clinical use by the need for parenteral administration.
Although nasal and other transmucosal routes can be used for CT treatment, bioavailability and bioactivity of the peptide
thus delivered are limited. We have evaluated the intrapulmonary route (IP) for the delivery of salmon calcitonin (SCT) in
normal subjects. SCT was administered with a dry powder delivery inhaler. For comparison, each subject also received intramuscular
(IM) SCT. Inhaled SCT produced significant hypocalcemia in all subjects as did injected SCT, and the peptide could be readily
measured in serum by immunoassay. Compared by dose, IP SCT had 66% of the bioactivity and 28% of the bioavailability of IM
SCT. This intrapulmonary route of administration should enhance the clinical acceptability of SCT and could also be applicable
to other bone-active peptides.
Received: 16 December 1996 / Accepted: 25 April 1997 |
| |
Keywords: | : Osteoporosis Hypercalcemia Anti-resorptive |
本文献已被 SpringerLink 等数据库收录! |
|